Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

AIMS : Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In this pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin on cardiovascular and non-cardiovascular causes of death. METHODS AND RESULTS : DAPA-CKD was an international,...

Descripción completa

Detalles Bibliográficos
Autores principales: Heerspink, Hiddo J L, Sjöström, C David, Jongs, Niels, Chertow, Glenn M, Kosiborod, Mikhail, Hou, Fan Fan, McMurray, John J V, Rossing, Peter, Correa-Rotter, Ricardo, Kurlyandskaya, Raisa, Stefansson, Bergur V, Toto, Robert D, Langkilde, Anna Maria, Wheeler, David C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clnical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244648/
https://www.ncbi.nlm.nih.gov/pubmed/33792669
http://dx.doi.org/10.1093/eurheartj/ehab094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244648/
https://www.ncbi.nlm.nih.gov/pubmed/33792669
http://dx.doi.org/10.1093/eurheartj/ehab094

Ejemplares similares